<html lang="en" class="pb-page js" data-request-id="94d6199fb251622c-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6199fb251622c-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/m9ejUfi-skV5_OOqydWpKbEwpxcNSax9mO4-CGx3oS5XAqgOUMQGV-NA8WDZ4VWoBIU2ZwvdzY_ulP0F6nwuVQ=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Treatment of Highly Drug-Resistant Pulmonary Tuberculosis | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6199fb251622c-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.19784371868833073"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Pulmonary/Critical Care|Infectious Disease">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Infectious Disease General|Tuberculosis|Global Health|Pulmonary/Critical Care General|HIV/AIDS"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1901814","title":"Treatment of Highly Drug-Resistant Pulmonary Tuberculosis","category":"Research","type":"Original Article","topics":"Infectious Disease General|Tuberculosis|Global Health|Pulmonary/Critical Care General|HIV/AIDS","specialties":"Pulmonary/Critical Care|Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-03-05T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Pulmonary/Critical Care|Infectious Disease\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Infectious Disease General|Tuberculosis|Global Health|Pulmonary/Critical Care General|HIV/AIDS\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1901814","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Visual Abstract","title":"Treatment of Highly Drug-Resistant Pulmonary TB","doi":"10.1056/NEJMdo005694","issueDate":"2020-03-05T00:00Z","age":"6Months-1990","isFree":"y","topics":"Tuberculosis|Infectious Disease General|Global Health|Pulmonary/Critical Care General|HIV/AIDS","viewType":"Full","specialties":"Pulmonary/Critical Care|Infectious Disease"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6199fb251622c-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Treatment of Highly Drug-Resistant Pulmonary Tuberculosis"><meta name="dc.Creator" content="Francesca Conradie"><meta name="dc.Creator" content="Andreas H. Diacon"><meta name="dc.Creator" content="Nosipho Ngubane"><meta name="dc.Creator" content="Pauline Howell"><meta name="dc.Creator" content="Daniel Everitt"><meta name="dc.Creator" content="Angela M. Crook"><meta name="dc.Creator" content="Carl M. Mendel"><meta name="dc.Creator" content="Erica Egizi"><meta name="dc.Creator" content="Joanna Moreira"><meta name="dc.Creator" content="Juliano Timm"><meta name="dc.Creator" content="Timothy D. McHugh"><meta name="dc.Creator" content="Genevieve H. Wills"><meta name="dc.Creator" content="Anna Bateson"><meta name="dc.Creator" content="Robert Hunt"><meta name="dc.Creator" content="Christo Van Niekerk"><meta name="dc.Creator" content="Mengchun Li"><meta name="dc.Creator" content="Morounfolu Olugbosi"><meta name="dc.Creator" content="Melvin Spigelman"><meta name="dc.Description" content="Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.In an open-label, single-group study in which follow-up is ongoing a..."><meta name="Description" content="Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.In an open-label, single-group study in which follow-up is ongoing a..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-03-05"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1901814"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202003053821005"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2000860"><meta name="dc.Relation" content="YXQYoa1901814"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright Â© 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1901814">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1901814">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1901814">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Treatment of Highly Drug-Resistant Pulmonary Tuberculosis | NEJM">
        <meta property="og:title" content="Treatment of Highly Drug-Resistant Pulmonary Tuberculosis | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1901814">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/ac13821c-6eef-4f39-bb07-3558a42d705c/nejmoa1901814_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/ac13821c-6eef-4f39-bb07-3558a42d705c/nejmoa1901814_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Patients with highly drug-resistant forms of tuberculosis have limited treatment options
and historically have had poor outcomes. In an open-label, single-group study in which
follow-up is ongoing ...">
        <meta name="twitter:description" content="Patients with highly drug-resistant forms of tuberculosis have limited treatment options
and historically have had poor outcomes. In an open-label, single-group study in which
follow-up is ongoing ...">
    


    
    
        <meta property="og:image:width" content="2207">
    


    
    
        <meta property="og:image:height" content="3438">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa1901814">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1901814">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;article:article:doi\:10.1056/NEJMoa1901814;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2020.382.issue-10;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1901814" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1901814" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1901814" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1901814" class="inputDoi"><input type="hidden" value="F. Conradie and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;382:893-902" class="inputCitation"><input type="hidden" value="03-04-2020" class="inputEPubDate"><input type="hidden" value="March 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Treatment of Highly Drug-Resistant Pulmonary Tuberculosis" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup modal-lg"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6199fb251622c-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Treatment of Highly Drug-Resistant Pulmonary Tuberculosis</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Francesca</span> <span property="familyName">Conradie</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andreas H.</span> <span property="familyName">Diacon</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nosipho</span> <span property="familyName">Ngubane</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pauline</span> <span property="familyName">Howell</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Daniel</span> <span property="familyName">Everitt</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Angela M.</span> <span property="familyName">Crook</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carl M.</span> <span property="familyName">Mendel</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+11</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Erica</span> <span property="familyName">Egizi</span>, <span property="honorificSuffix">M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joanna</span> <span property="familyName">Moreira</span>, <span property="honorificSuffix">B.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Juliano</span> <span property="familyName">Timm</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Timothy D.</span> <span property="familyName">McHugh</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Genevieve H.</span> <span property="familyName">Wills</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anna</span> <span property="familyName">Bateson</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert</span> <span property="familyName">Hunt</span>, <span property="honorificSuffix">B.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christo</span> <span property="familyName">Van Niekerk</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mengchun</span> <span property="familyName">Li</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Morounfolu</span> <span property="familyName">Olugbosi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Melvin</span> <span property="familyName">Spigelman</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the Nix-TB Trial Team<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-11</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">March 4, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">382</span></span>:<span property="pageStart">893</span>-<span property="pageEnd">902</span></div><div class="doi">DOI: 10.1056/NEJMoa1901814</div><div class="core-enumeration"><a href="/toc/nejm/382/10"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">382</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">10</span></span></a></div><div><a href="#tab-information">Copyright Â© 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DFrancesca%2BConradie%252C%2BAndreas%2BH.%2BDiacon%252C%2BNosipho%2BNgubane%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D10%26contentID%3D10.1056%252FNEJMoa1901814%26title%3DTreatment%2Bof%2BHighly%2BDrug-Resistant%2BPulmonary%2BTuberculosis%26publicationDate%3D03%252F05%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1901814" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DFrancesca%2BConradie%252C%2BAndreas%2BH.%2BDiacon%252C%2BNosipho%2BNgubane%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D10%26contentID%3D10.1056%252FNEJMoa1901814%26title%3DTreatment%2Bof%2BHighly%2BDrug-Resistant%2BPulmonary%2BTuberculosis%26publicationDate%3D03%252F05%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/82710ea1-f332-411d-8118-2f233df55151/nejmoa1901814.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1901814.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1901814" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1901814" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1901814.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs â bedaquiline, pretomanid, and linezolid â that have bactericidal activity against tuberculosis and to which there is little preexisting resistance. We evaluated the safety and efficacy of the drug combination for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects. The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriologic or clinical) or relapse during follow-up, which continued until 6 months after the end of treatment. Patients were classified as having a favorable outcome at 6 months if they had resolution of clinical disease, a negative culture status, and had not already been classified as having had an unfavorable outcome. Other efficacy end points and safety were also evaluated.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points. At 6 months after the end of treatment in the intention-to-treat analysis, 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome. The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up. The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose reductions or interruptions in treatment with linezolid.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed. (Funded by the TB Alliance and others; ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02333799" target="_blank">NCT02333799</a>.)</div></section></section><div class="core-digital-object visual-abstract">
<div class="ng-page_separator pt-24"></div>
<div class="ng-do-media">
    <button data-toggle="modal" data-target="#doPopup" class="ng-do-media_btn" modal-size="lg"></button>
    <div data-ajaxurl="/do/10.1056/NEJMdo005694/full/?ajaxRequest=true" class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="#" class="ng-do-media_item-img-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005694" data-multimedia-filename="NEJMdo005694_600x400.jpg">
                <img src="/cms/asset/5e3835ed-765a-4c47-9f92-807fc959bb92/media/NEJMdo005694_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-visual"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/visual-abstract" class="ng-do-media_item-type-link">Visual Abstract</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="#" class="ng-do-media_item-title-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005694" data-multimedia-filename="NEJMdo005694_600x400.jpg">Treatment of Highly Drug-Resistant Pulmonary TB</a>
            </h6>
        </div>
    </div>
</div>

</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">The vision of the End TB strategy of the World Health Organization (WHO) is of a world free of tuberculosis by the year 2035.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> However, extensively drug-resistant (XDR) tuberculosis (i.e., tuberculosis with resistance to isoniazid, rifampin, any fluoroquinolone, and at least one injectable drug [amikacin, capreomycin, or kanamycin]) and complicated forms of multidrug-resistant (MDR) tuberculosis (i.e., tuberculosis with resistance to isoniazid and rifampin that does not respond to treatment or for which treatment is discontinued because of side effects) pose threats to the achievement of this goal because of the lack of effective treatment for these forms of the disease.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2" href-manipulated="true" aria-label="Reference 2">2</a></sup></div><div role="paragraph">Five years ago, the typical duration of treatment of MDR tuberculosis ranged from 18 months to more than 2 years, with some patients receiving up to seven medications, including a second-line injectable. The incidence of side effects with these regimens is high, with 45% of patients having moderate-to-severe adverse events.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3" href-manipulated="true" aria-label="Reference 3">3</a></sup> Patients with XDR tuberculosis had few treatment options and no standard treatment regimen. The published success rates for treatment of XDR tuberculosis were low and consistent across South Africa, averaging 14% and ranging from 2 to 22%.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5" id="body-ref-r5" href-manipulated="true">4,5</a></sup></div><div role="paragraph">Bedaquiline is a diarylquinoline that inhibits mycobacterial ATP synthase.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6" href-manipulated="true" aria-label="Reference 6">6</a></sup> In a phase 2 study of bedaquiline added to a background regimen, 23 of 38 patients with XDR tuberculosis (61%) had had a response at 120 weeks after the initiation of treatment.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7" href-manipulated="true" aria-label="Reference 7">7</a></sup> There has been increased early access to this medication, especially in South Africa. In the cohort of patients with XDR tuberculosis who started treatment between July 2014 and March 2016, bedaquiline-containing regimens were associated with a lower risk of death from any cause than were regimens that did not contain bedaquiline (hazard ratio, 0.26, 95% confidence interval [CI], 0.18 to 0.38).<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-1" href-manipulated="true" aria-label="Reference 8">8</a></sup></div><div role="paragraph">Linezolid, an oxazolidinone that has been approved in many countries for the treatment of drug-resistant, gram-positive bacterial infections, inhibits bacterial protein synthesis.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9" href-manipulated="true" aria-label="Reference 9">9</a></sup> Resistance of <i>Mycobacterium tuberculosis</i> to linezolid is rare, since this drug has not been widely used to treat tuberculosis. A recent evaluation of 420 XDR and MDR <i>M. tuberculosis</i> strains in South Korea showed 1 strain (0.3%) with resistance at the WHO-recommended cutoff value.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10" href-manipulated="true" aria-label="Reference 10">10</a></sup></div><div role="paragraph">Pretomanid, a nitroimidazooxazine that inhibits mycolic acid biosynthesis and thereby blocks mycobacterial cell-wall production, also acts as a respiratory poison against nonreplicating bacteria after nitric oxide release under anaerobic conditions.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12" id="body-ref-r12" href-manipulated="true">11,12</a></sup> Pretomanid has in vitro activity against both drug-susceptible and drug-resistant (including XDR) strains of <i>M. tuberculosis</i> and has in vivo activity in animal models of tuberculosis.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14" id="body-ref-r14" href-manipulated="true">13,14</a></sup> Phase 2 studies to evaluate the early bactericidal activity of pretomanid over 14 days of daily oral monotherapy showed that the lowest dose to produce a maximal effect for early bactericidal activity was 100 mg per day.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> Pretomanid was recently approved by the Food and Drug Administration (FDA) under the Limited Population Pathway for Antibacterial and Antifungal Drugs as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary XDR tuberculosis or with complicated MDR tuberculosis. Here, we present the results of the Nix-TB study, which evaluated the safety, side-effect profile, efficacy, and pharmacokinetics of this oral regimen.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Study Design</h3><div role="paragraph">Nix-TB is an open-label, single-group study involving patients with XDR tuberculosis and patients with MDR tuberculosis that is not responsive to treatment or for which a second-line regimen had been discontinued because of side effects. All patients received 26 weeks of daily oral treatment, with an option to extend treatment to 39 weeks if they were culture-positive at week 16. An interim analysis for safety was conducted after every 15 enrollments.</div></section><section id="sec-1-2"><h3>Study Patients</h3><div role="paragraph">Patients were enrolled from three study sites in South Africa: Sizwe Tropical Disease Hospital, Johannesburg; Task Applied Science at Brooklyn Chest Hospital, Cape Town; and King DiniZulu Hospital Complex, Durban. Patients 14 years of age or older were eligible for enrollment. The major inclusion criteria were pulmonary XDR or MDR tuberculosis documented on culture or molecular testing within 3 months before screening, with drug resistance documented by phenotypic or genotypic testing followed by, in patients with MDR tuberculosis, documentation of nonresponse to treatment with an available regimen for 6 months or more before enrollment or an inability to continue a second-line drug regimen because of documented side effects from treatment. Human immunodeficiency virus (HIV)âinfected patients with a CD4+ cell count of greater than 50 per cubic millimeter could be enrolled and appropriate antiretroviral treatment given (Table S1 in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org). Patients with baseline peripheral neuropathy of grade 3 or 4 were excluded. Detailed inclusion and exclusion criteria are provided in the <a href="#ap1">protocol</a>, available at NEJM.org. All patients provided written informed consent.</div></section><section id="sec-1-3"><h3>Enrollment and Intervention</h3><div role="paragraph">Patients received orally administered treatment as follows: bedaquiline at a dose of 400 mg once daily for 2 weeks followed by 200 mg three times a week for 24 weeks, plus pretomanid at a dose of 200 mg daily for 26 weeks and linezolid at a dose of 1200 mg daily for up to 26 weeks (with dose adjustment depending on the toxic effects). The total daily dose of linezolid of 1200 mg was changed from 600 mg twice daily to 1200 mg once daily during the study to evaluate whether a single daily dose, which would reduce the exposures above the potential threshold for mitochondrial protein synthesis toxicity, would have less clinical toxicity. More details are provided in the protocol. All patients underwent screening within 9 days before receiving the first dose of the study treatment (day 1) and were seen weekly thereafter to week 16, at weeks 20 and 26, and then at months 1, 2, and 3 after the end of treatment and every 3 months thereafter, to 24 months after the end of treatment.</div></section><section id="sec-1-4"><h3>Microbiologic Assessments</h3><div role="paragraph">Two sputum samples were obtained for smear microscopy and culture (performed by means of the Mycobacteria Growth Indicator Tube [MGIT] method) at screening; baseline; weeks 1, 2, 4, 6, 8; and then monthly through week 26 and in follow-up months 1, 2, 3 and every 3 months through month 24. <i>M. tuberculosis</i> was identified by molecular methods. <i>M. tuberculosis</i> isolates obtained at baseline and at the end of treatment or during follow-up were transferred to a central laboratory for the determination of the minimum inhibitory concentration (MIC) of bedaquiline, pretomanid, and linezolid; for MGIT drug-susceptibility testing for rifampin, isoniazid, streptomycin, ethambutol, moxifloxacin, and kanamycin; and for paired whole-genome sequencing. The laboratory manual includes full details of the microbiologic procedures.</div></section><section id="sec-1-5"><h3>Safety</h3><div role="paragraph">Assessments of safety included regular electrocardiography and examination of blood samples, with particular attention paid to expected hematologic toxic effects. Ophthalmologic examination, including assessment of visual acuity and color vision, was performed every 4 weeks, and a slit-lamp examination for cataracts performed at screening, at the end of treatment, and 3 months later. Changes were noted in signs and symptoms of peripheral neuropathy, including any changes from baseline, with the use of a Brief Peripheral Neuropathy rating scale that evaluated subjective symptoms and objective measures of deep-tendon reflexes and vibration sense.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup></div></section><section id="sec-1-6"><h3>Outcome Measures and End Points</h3><div role="paragraph">The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriologic or clinical) or disease relapse. Clinical treatment failure was defined as a change from the protocol-specified tuberculosis treatment as a result of a lack of clinical efficacy, retreatment for tuberculosis, or tuberculosis-related death through follow-up until 6 months after the end of treatment. Patients were considered to have had a favorable outcome if their clinical tuberculosis disease had resolved, they had a negative culture status at 6 months after the end of therapy, and they had not already been classified as having had an unfavorable outcome. Secondary end points included the time to an unfavorable outcome and the time to sputum culture conversion through the treatment period. Culture conversion was defined as at least two consecutive culture-negative samples collected at least 7 days apart.</div><div role="paragraph">Safety and adverse-event end points included all-cause mortality and the incidence of adverse events that occurred or worsened during the treatment period, defined here as the period from the start of treatment through 14 days after the end of treatment. The severity of adverse events was categorized according to grade, as defined by the Division of Microbiology and Infectious Diseases,<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> as well as according to whether they were judged by the investigators to be related to the study medication.</div></section><section id="sec-1-7"><h3>Study Oversight</h3><div role="paragraph">An independent data and safety monitoring committee oversaw the safety of the study and provided advisement about whether to continue without changes after each review. Although there were no formal stopping rules, recommendations for early stopping or modification of the study were left to the discretion of the data and safety monitoring committee. National and local ethics committees approved the study. The Food and Drug Administration and the Medicines Control Council in South Africa reviewed the protocol. The authors vouch for the accuracy and completeness of the data and for the fidelity of the study to the protocol.</div></section><section id="sec-1-8"><h3>Statistical Analysis</h3><div role="paragraph">No formal statistical power calculation was performed; however, we prespecified that the regimen would be determined to be effective if the lower bound of the 95% confidence interval of the percentage of patients with a favorable outcome was greater than 50% (see Section 7 of the Efficacy Statistical Analysis Plan, available with the protocol at NEJM.org). Although the protocol allowed enrollment of up to 200 patients, enrollment stopped after 109 when ZeNix, a randomized trial investigating linezolid dosing and duration in the context of treatment with bedaquiline, pretomanid, and linezolid (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03086486" target="_blank">NCT03086486</a>), was started. All analyses were performed with Stata software, version 15.1 (StataCorp).</div><div role="paragraph">Intention-to-treat and modified intention-to-treat analyses were prespecified as the primary analyses, and a per-protocol analysis was also performed. However, the populations were similar, and for ease of interpretation we report the intention-to-treat analysis with no exclusions. More details on the definitions of the analysis populations are provided in the protocol.</div><div role="paragraph">We calculated percentages (with exact 95% confidence intervals) of the assessable patients who had a favorable outcome. Subgroup analyses of the primary outcome according to the type of tuberculosis (XDR or MDR), HIV status, and dosing schedule of linezolid were performed to evaluate the consistency of the results. No formal statistical tests were performed. The time to an unfavorable outcome and time to culture-negative status were analyzed with standard time-to-event analysis techniques, including KaplanâMeier plots.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">In total, 34 potential participants were excluded during screening (Table S2), and 109 patients were enrolled in the study between April 16, 2015, and November 15, 2017, and included in the analysis of efficacy and safety. The first 44 patients were started on linezolid at 600 mg twice daily, and the remaining 65 were started on 1200 mg daily. Two patients who had positive cultures during treatment (one at month 4 and one at month 5) had their treatment extended for an additional 3 months. Follow-up to 24 months after the end of treatment is ongoing.</div><div role="paragraph">The demographic and clinical characteristics of the patients are given in <a href="#t1">Table 1</a>. The median age was 35 years (range, 17 to 60 years), 57 patients (52%) were male, 56 (51%) were HIV-positive, 92 (84%) had cavities on chest radiographs, and the median body-mass index (the weight in kilograms divided by the square of the height in meters) was 19.7. All patients with HIV coinfection were treated with antiretroviral therapy during the trial, and all except 2 had been receiving antiretroviral therapy before enrollment. The median time since the original diagnosis of tuberculosis was 12 months (range, &lt;1 to 141 months). All except 9 patients had received tuberculosis medications in the month before enrollment, with the most common drugs used (by â¥55 patients) being fluoroquinolones, pyrazinamide, terizidone, clofazimine, para-aminosalicylic acid, ethambutol, and ethionamide, with a median of 7 (range, 3 to 13) tuberculosis drugs being taken. A total of 71 cases (65%) were classified as XDR tuberculosis, 19 (17%) were classified as MDR tuberculosis that did not respond to treatment, and 19 (17%) were classified as MDR tuberculosis for which treatment was stopped because of side effects.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t1.jpg"><img src="/cms/10.1056/NEJMoa1901814/asset/260baecd-5650-4083-9b98-6010b3cedd34/assets/images/large/nejmoa1901814_t1.jpg" height="1958" width="1136" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxr-borders">Value<br>(N=109)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Median age (range) â yr</td><td class="xxxr-borders shading" data-xml-align="center">35 (17â60)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Male sex â no. (%)</td><td class="xxxr-borders" data-xml-align="center">57 (52)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race â no. (%)<a href="#t1fn2" role="doc-noteref">â </a></td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Black</td><td class="xxxr-borders" data-xml-align="center">83 (76)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Mixed race</td><td class="xxxr-borders shading" data-xml-align="center">25 (23)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">White</td><td class="xxxr-borders" data-xml-align="center">1 (1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Median BMI (range)<a href="#t1fn3" role="doc-noteref">â¡</a></td><td class="xxxr-borders shading" data-xml-align="center">19.7 (12.4â41.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">HIV-positive â no. (%)</td><td class="xxxr-borders" data-xml-align="center">56 (51)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Median time since HIV diagnosis (range) â yr</td><td class="xxxr-borders shading" data-xml-align="center">4.0 (0.2â14.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Median CD4 cell count (range) â cells/mm<sup>3</sup><a href="#t1fn4" role="doc-noteref">Â§</a></td><td class="xxxr-borders" data-xml-align="center">343 (55â1023)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Cavities present on chest radiograph â no. (%)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">No</td><td class="xxxr-borders" data-xml-align="center">17 (16)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Unilateral</td><td class="xxxr-borders shading" data-xml-align="center">51 (47)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Bilateral</td><td class="xxxr-borders" data-xml-align="center">41 (38)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Karnofsky score â no. (%)<a href="#t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">100</td><td class="xxxr-borders" data-xml-align="center">9 (8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">90</td><td class="xxxr-borders shading" data-xml-align="center">50 (46)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">80</td><td class="xxxr-borders" data-xml-align="center">29 (27)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">70</td><td class="xxxr-borders shading" data-xml-align="center">19 (17)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">60</td><td class="xxxr-borders" data-xml-align="center">2 (2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">&lt;60</td><td class="xxxr-borders shading" data-xml-align="center">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Median no. of tuberculosis drugs taken in month before enrollment (range)</td><td class="xxxr-borders" data-xml-align="center">7 (3â13)</td></tr><tr data-type="row"><td class="xblx-borders hanging02 shading">Median time since original tuberculosis diagnosis (range) â mo</td><td class="xbxr-borders shading" data-xml-align="center">12 (&lt;1â141)</td></tr></tbody></table></div><figcaption><div class="caption">Baseline Characteristics of the Patients.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Percentages may not total 100 because of rounding. HIV denotes human immunodeficiency virus.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t1fn2" role="paragraph">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t1fn3" role="paragraph">Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t1fn4" role="paragraph">Data on CD4 cell count were missing for 5 patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t1fn5" role="paragraph">The Karnofsky score ranges from 0 to 100, with lower scores indicating greater disability.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Microbiologic Assessment</h3><div role="paragraph">All patients met the inclusion criterion of having tuberculosis with documented resistance to antituberculosis drugs and were categorized as having either XDR or MDR tuberculosis, although 16 patients did not have positive baseline cultures. Baseline isolates for 57 patients could be evaluated for MICs of all study drugs. In all but three isolates, bedaquiline and linezolid MICs were below or equal to the critical concentration recommended by the WHO (1 Î¼g per milliliter for both drugs).<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> Two baseline isolates had bedaquiline MICs equal to 2 Î¼g per milliliter, and one had a bedaquiline MIC equal to 4 Î¼g per milliliter. All the baseline isolates tested had pretomanid MICs of 1 Î¼g per milliliter or lower. Among the surviving patients, the median number of cultures obtained to determine the primary end point was 29 (range, 20 to 40).</div></section><section id="sec-2-3"><h3>Efficacy Analysis</h3><div role="paragraph">At 6 months after the end of treatment in the intention-to-treat analysis, 11 patients (10%) had an unfavorable outcome. The 11 unfavorable outcomes were 7 deaths (6 during treatment; 1 during follow-up from an unknown cause that was not considered by the investigators to be tuberculosis- or drug-related), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up.</div><div role="paragraph">The number of patients classified as having a favorable outcome in the intention-to-treat analysis was 98 (90%; 95% CI, 83 to 95), with similar findings in the modified intention-to-treat and per-protocol analyses (<a href="#t2">Table 2</a>). These results had a lower bound of the 95% confidence interval that was greater than 50% (<a href="#t2">Table 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t2.jpg"><img src="/cms/10.1056/NEJMoa1901814/asset/38a2bee1-1a84-41a0-8d74-531bd27bc18b/assets/images/large/nejmoa1901814_t2.jpg" height="2263" width="1712" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">XDR</th><th class="txxx-borders">MDR</th><th class="txxr-borders">Overall</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Intention-to-treat population</b><a href="#t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">71</td><td class="xxxx-borders">38</td><td class="xxxr-borders">109</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Favorable outcome</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients</td><td class="xxxx-borders">63</td><td class="xxxx-borders">35</td><td class="xxxr-borders">98</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders shading">89 (79â95)</td><td class="xxxx-borders shading">92 (79â98)</td><td class="xxxr-borders shading">90 (83â95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Unfavorable outcome â no. (%)</td><td class="xxxx-borders">8 (11)</td><td class="xxxx-borders">3 (8)</td><td class="xxxr-borders">11 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Deaths â no.</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Withdrawal during treatment â no.</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Lost to follow-up after end of treatment â no.</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Relapse â no.</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1</td><td class="xxxr-borders">2<a href="#t2fn3" role="doc-noteref">â¡</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Modified intention-to-treat population</b><a href="#t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">70</td><td class="xxxx-borders">37</td><td class="xxxr-borders">107</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Favorable outcome</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients</td><td class="xxxx-borders">63</td><td class="xxxx-borders">35</td><td class="xxxr-borders">98</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders shading">90 (80â96)</td><td class="xxxx-borders shading">95 (82â99)</td><td class="xxxr-borders shading">92 (85â96)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Unfavorable outcome â no. (%)</td><td class="xxxx-borders">7 (10)</td><td class="xxxx-borders">2 (5)</td><td class="xxxr-borders">9 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Deaths â no.</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Withdrawal during treatment â no.</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Relapse â no.</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">2<a href="#t2fn3" role="doc-noteref">â¡</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Per-protocol population</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">68</td><td class="xxxx-borders shading">37</td><td class="xxxr-borders shading">105</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Favorable outcome</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">62</td><td class="xxxx-borders shading">35</td><td class="xxxr-borders shading">97</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders">91 (82â97)</td><td class="xxxx-borders">95 (82â99)</td><td class="xxxr-borders">92 (86â97)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Unfavorable outcome â no. (%)</td><td class="xxxx-borders shading">6 (9)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxr-borders shading">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Deaths â no.</td><td class="xxxx-borders">5</td><td class="xxxx-borders">1</td><td class="xxxr-borders">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Relapse â no.</td><td class="xbxx-borders shading">1</td><td class="xbxx-borders shading">1</td><td class="xbxr-borders shading">2<a href="#t2fn3" role="doc-noteref">â¡</a></td></tr></tbody></table></div><figcaption><div class="caption">Primary Efficacy Analysis.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">An unfavorable outcome was defined as treatment failure (bacteriologic or clinical) or disease relapse, with clinical treatment failure defined as a change from the protocol-specified tuberculosis treatment as a result of treatment failure, retreatment for tuberculosis, or tuberculosis-related death through follow-up until 6 months after the end of treatment. Patients were considered to have had a favorable outcome if their clinical tuberculosis disease had resolved, they had a negative culture status at 6 months after the end of therapy, and they had not already been classified as having had an unfavorable outcome. All patients in this study had either a favorable or an unfavorable outcome at 6 months after the end of treatment.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t2fn2" role="paragraph">The intention-to-treat and modified intention-to-treat analyses were prespecified in the protocol. Two patients were excluded from the modified intention-to-treat population: one who died from nonâtuberculosis-related causes during follow-up, and one who was lost to follow-up after the end of treatment. Two additional patients were excluded from the per-protocol population: one who received an inadequate amount of drug, and one who was withdrawn (not for treatment failure) during treatment.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t2fn3" role="paragraph">A baseline isolate was not available for one patient who had a relapse.</div></div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Subgroup Analyses</h3><div role="paragraph">The results were similar when stratified according to tuberculosis type. Among the 71 patients with XDR tuberculosis in the intention-to-treat population, the number classified as having a favorable outcome was 63 (89%; 95% CI, 79 to 95), and among the 38 patients with MDR tuberculosis, 35 were classified as having a favorable outcome (92%; 95% CI, 79 to 98) (<a href="#t2">Table 2</a>). The results were also consistent regardless of HIV status and linezolid dosing scheme.</div><div role="paragraph">The time to an unfavorable outcome, overall and stratified according to tuberculosis type, HIV status, and linezolid dosing, is shown in <a href="#f1">Figure 1</a>. KaplanâMeier estimates of the time to culture-negative status, overall and stratified according to tuberculosis type, are shown in <a href="#f2">Figure 2</a>. There were two relapses. Whole-genome sequencing performed on the corresponding baseline and late isolates confirmed that one patient had a relapse with the same strain of <i>M. tuberculosis</i> (only 5 single-nucleotide polymorphisms [SNPs] separated the two isolates). One of these SNPs produced a change in the bedaquiline resistance gene <i>Rv0678</i>, from wild type at baseline to a 138-139insG variant in the late isolate. The bedaquiline MIC was elevated in the late isolate (4 Î¼g per milliliter, as compared with 0.5 Î¼g per milliliter at baseline).<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> The second patient who had a relapse did not have a baseline isolate available for testing, but the late isolate was analyzed and was shown to be susceptible to all three study drugs.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1901814_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1901814_f1.jpg"><img src="/cms/10.1056/NEJMoa1901814/asset/ac13821c-6eef-4f39-bb07-3558a42d705c/assets/images/large/nejmoa1901814_f1.jpg" height="3438" width="2207" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Time to an Unfavorable Outcome (Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">An unfavorable outcome was defined as treatment failure (bacteriologic or clinical) or disease relapse, with clinical treatment failure defined as a change from the protocol-specified tuberculosis treatment as a result of treatment failure, retreatment for tuberculosis, or tuberculosis-related death through follow-up until 6 months after the end of treatment. MDR denotes multidrug-resistant, and XDR extensively drug-resistant.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1901814_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1901814_f2.jpg"><img src="/cms/10.1056/NEJMoa1901814/asset/d8403b96-9bf0-4e58-9776-9c2d4b8f2986/assets/images/large/nejmoa1901814_f2.jpg" height="3438" width="2225" aria-labelledby="f2" loading="lazy"></a><figcaption>Time to Culture-Negative Status among Patients Who Were Positive at Baseline (Intention-to-Treat Population).</figcaption></figure></div></section><section id="sec-2-5"><h3>Safety Analysis</h3><div role="paragraph">All patients had at least one adverse event that occurred or worsened during treatment, and 19 (17%) had serious adverse events, which were similar in frequency regardless of whether patients were HIV-positive or HIV-negative. Six patients died during the course of treatment (1 patient at month 1, 4 at month 2, and 1 at month 3; an additional patient died from sepsis and gangrene after relapse of tuberculosis). A total of 62 patients (57%) had adverse events of grade 3 or higher that occurred or worsened during treatment; the percentage of patients with such an event did not differ substantially according to HIV status (<a href="#t3">Table 3</a>). Details of the adverse events and deaths are provided in Tables S3, S4, and S5.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t3.jpg"><img src="/cms/10.1056/NEJMoa1901814/asset/96a0a1ed-9765-46b1-a3bf-f349d1fb9951/assets/images/large/nejmoa1901814_t3.jpg" height="714" width="1712" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event<a href="#t3fn1" role="doc-noteref">*</a></th><th class="txxx-borders" colspan="2"><span>HIV Status</span></th><th class="txxx-borders" colspan="2"><span>Linezolid Regimen</span></th><th class="txxr-borders">Overall<br>(N=109)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Negative<br>(N=53)</th><th class="xxxx-borders">Positive<br>(N=56)</th><th class="xxxx-borders">600 mg Twice Daily<br>(N=44)</th><th class="xxxx-borders">1200 mg Daily<br>(N=65)</th><th class="xxxr-borders">&nbsp;</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="5"><span>number (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Adverse event</td><td class="xxxx-borders shading">53 (100)</td><td class="xxxx-borders shading">56 (100)</td><td class="xxxx-borders shading">44 (100)</td><td class="xxxx-borders shading">65 (100)</td><td class="xxxr-borders shading">109 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Adverse event leading to death</td><td class="xxxx-borders">3 (6)</td><td class="xxxx-borders">3 (5)</td><td class="xxxx-borders">4 (9)</td><td class="xxxx-borders">2 (3)</td><td class="xxxr-borders">6 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">10 (19)</td><td class="xxxx-borders shading">9 (16)</td><td class="xxxx-borders shading">13 (30)</td><td class="xxxx-borders shading">6 (9)</td><td class="xxxr-borders shading">19 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Grade 3 or 4 adverse event</td><td class="xbxx-borders">27 (51)</td><td class="xbxx-borders">35 (62)</td><td class="xbxx-borders">27 (61)</td><td class="xbxx-borders">35 (54)</td><td class="xbxr-borders">62 (57)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events That Occurred or Worsened during Treatment.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">A patient could have had more than one type of event.</div></div></div></figcaption></figure></div><div role="paragraph">During treatment, 88 patients (81%) were reported to have peripheral neuropathy; in the majority of cases, the symptoms were mild to moderate. Among patients whose mean score on the Brief Peripheral Neuropathy Screening scale indicated moderate to severe neuropathy, the median time to a return to a score indicating no or mild neuropathy was 3 months. Patients are continuing in follow-up, and the time course of the resolution of neuropathy is undergoing further analysis. Figure S1A shows the time to a first linezolid dose reduction or interruption for neuropathy; the majority of these events occurred after the initial 3 months of treatment. Results were similar for patients who were coinfected with HIV and those who were HIV-uninfected and for patients who initially received linezolid at 600 mg twice a day and those who received linezolid at 1200 mg daily. Optic neuritis developed in 2 patients, which resolved on withdrawal of linezolid. Blood and lymphatic system disorders were the second most common adverse events that occurred or worsened during treatment: myelosuppression occurred in 52 patients (48%); 40 of these patients (37% of the study population) had anemia, 7 of whom had hemoglobin decreases to less than 8.0 g per deciliter. Figure S1B shows the time to a first linezolid dose reduction or interruption for anemia. In the majority of patients with this event, it occurred during the first 2 months of treatment, with similar results observed in HIV-coinfected and -uninfected patients and in patients who received different starting doses of linezolid.</div><div role="paragraph">Aminotransferase increases occurred in 17 patients; 12 had an alanine aminotransferase (ALT) elevation and 11 an aspartate aminotransferase (AST) elevation to a level higher than 3 times the upper limit of the normal range. Two of these patients had ALT and AST elevations to more than 3 times the upper limit of the normal range, as well as direct and total bilirubin elevations to more than 2 times the upper limit of the normal range. In both cases, the study regimen was interrupted. Eight patients had the regimen interrupted for hepatic adverse events, but all resumed and completed the full 26 weeks of treatment. The maximum mean increase in the QT interval, as assessed with Fridericiaâs formula, was 10 msec at week 16; no patient had an increase of more than 480 msec.</div><div role="paragraph">All surviving patients completed 26 weeks of treatment (including two who extended to 39 weeks); only one of these patients had a treatment interruption longer than the allowed 35 consecutive days, and none had the regimen permanently discontinued. Most patients had a reduction in dose or an interruption of linezolid during treatment. In total, 37 patients (34%) completed 26 weeks of linezolid treatment without any interruption, although they may have had a dose reduction, and 16 (15%) completed 26 weeks at a total daily dose of 1200 mg of linezolid with no interruptions or dose reductions.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">At 6 months after the completion of therapy, 98 patients (90%) were found to have a favorable outcome, including 63 of 71 patients (89%) with XDR tuberculosis. Of the 38 patients with MDR tuberculosis who were enrolled in the study, 35 (92%) had favorable outcomes.</div><div role="paragraph">One of the limitations of this study is that there is no randomized control group. At the time of implementing this protocol, there was no standard regimen for the treatment of XDR tuberculosis. Mortality was high, with long-term cure occurring in less than 20% of patients in reports from South Africa, and a single-group study was therefore warranted. However, during the course of this study, both bedaquiline and linezolid have been increasingly used to treat MDR tuberculosis and XDR tuberculosis, and the WHO recently published guidelines that recommend these two drugs as first-line treatment for MDR tuberculosis over an 18-month course of therapy.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> Bedaquiline has been shown recently in a programmatic context to reduce overall mortality when added to treatment for MDR and XDR tuberculosis.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r21 r22" id="body-ref-r22" href-manipulated="true">8,21,22</a></sup> Among patients with XDR tuberculosis who were treated in Cape Town, South Africa, at one of the sites of the Nix-TB study, the percentage of patients who were cured was below 20% before the use of bedaquiline or linezolid and has improved to 66% more recently, since bedaquiline and linezolid were added to the regimens (all the patients received bedaquiline, and 81% also received linezolid).<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> Of note, these patients had newly diagnosed XDR tuberculosis and were treated for 24 months with a median of eight drugs.</div><div role="paragraph">Another limitation of this study is that it was conducted in only one country, which potentially limits the generalizability of the findings. South Africa was selected because it has a robust regulatory framework, good clinical trial capacity, and historically poor outcomes among patients with XDR tuberculosis. In addition, there is a high background prevalence of HIV infection.</div><div role="paragraph">The primary end point in this study was based on an unfavorable outcome at 6 months after the end of treatment, since most relapses occur during this period.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> The secondary end point of the incidence of treatment failure is being measured at 24 months after the end of treatment. It is reassuring that to date there has been only one additional relapse among the 47 patients who have reached this time point in the study with final follow-up and cultures.</div><div role="paragraph">For both individual patients with tuberculosis and national tuberculosis programs, a shorter duration of treatment that is effective is beneficial. Visits to health care facilities place a financial and time burden on patients. Income loss often constitutes the largest financial risk for patients. For tuberculosis programs, a shorter duration of treatment translates into fewer patients being in care at any one time, with the potential to reduce loss to follow-up.</div><div role="paragraph">A high percentage of patients had adverse events related to linezolid during the study: 81% of the patients reported peripheral neuropathy, and almost half had evidence of hematologic toxic effects. Although patients taking this regimen should be monitored carefully, these toxic effects were manageable in our study. All eight patients who had the regimen interrupted for hepatic adverse events resumed and completed the full 26 weeks of treatment.</div><div role="paragraph">This study shows that XDR tuberculosis and complicated MDR tuberculosis can be treated with a regimen consisting of three oral agents for 26 weeks. Despite these forms of tuberculosis being historically hard-to-treat conditions, treatment success was 90%, which is similar to that obtained with the standard of care (i.e., isoniazid, rifampin, pyrazinamide, and ethambutol) in modern trials of treatment for drug-sensitive tuberculosis.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25 r26 r27" id="body-ref-r27" href-manipulated="true">25-27</a></sup></div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="version-of-record" role="paragraph">This is the <i>New England Journal of Medicine</i> version of record, which includes all <i>Journal</i> editing and enhancements. The Author Final Manuscript, which is the authorâs version after external peer review and before publication in the <i>Journal</i>, is available under a CC BY license at <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955640/" target="_blank">PMC6955640</a>.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by the TB Alliance (Global Alliance for TB Drug Development), the <span class="named-content" data-type="funder">U.K. Department for International Development</span>, the <span class="named-content" data-type="funder">U.K. Department of Health</span>, the <span class="named-content" data-type="funder">Bill and Melinda Gates Foundation</span>, the <span class="named-content" data-type="funder">U.S. Agency for International Development</span>, the <span class="named-content" data-type="funder">Directorate General for International Cooperation of the Netherlands</span>, <span class="named-content" data-type="funder">Irish Aid</span>, the Australia <span class="named-content" data-type="funder">Department of Foreign Affairs and Trade</span>, the <span class="named-content" data-type="funder">Federal Ministry for Education and Research of Germany through KfW</span> (a state-owned development bank that handles the grants to product development partnerships, such as the TB Alliance, for the German government), a grant (MC_UU_12023/27 Tuberculosis Treatment Trials) from the Medical Research Council (to Dr. Crook), and a grant from the <span class="named-content" data-type="funder">National Research Foundation of South Africa</span> (to Dr. Diacon).</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank all the study patients; the nursing and laboratory staff; colleagues at Janssen Pharmaceuticals; all those who advised, volunteered, or otherwise supported community engagement around the Nix-TB clinical study sites; and the members of the data and safety monitoring committee for their oversight.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1901814_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1901814/suppl_file/nejmoa1901814_protocol.pdf" download="nejmoa1901814_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1901814_protocol.pdf" data-doi="10.1056/NEJMoa1901814">Download</a></li><li>15.03 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1901814_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1901814/suppl_file/nejmoa1901814_appendix.pdf" download="nejmoa1901814_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1901814_appendix.pdf" data-doi="10.1056/NEJMoa1901814">Download</a></li><li>1.18 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1901814_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1901814/suppl_file/nejmoa1901814_disclosures.pdf" download="nejmoa1901814_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1901814_disclosures.pdf" data-doi="10.1056/NEJMoa1901814">Download</a></li><li>427.25 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1901814_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1901814/suppl_file/nejmoa1901814_data-sharing.pdf" download="nejmoa1901814_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1901814_data-sharing.pdf" data-doi="10.1056/NEJMoa1901814">Download</a></li><li>68.83 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">The end TB strategy. Geneva: World Health Organization, 2014 (<a href="http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1">http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=The+end+TB+strategy.+Geneva%3A+World+Health+Organization%2C+2014+%28http%3A%2F%2Fwww.who.int%2Ftb%2Fstrategy%2FEnd_TB_Strategy.pdf%3Fua%3D1%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Gandhi NR, Andrews JR, Brust JC, et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. <em>Int J Tuberc Lung Dis</em> 2012;16:90-97.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5588/ijtld.11.0153" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22236852/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000298726700017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+factors+for+mortality+among+MDR-+and+XDR-TB+patients+in+a+high+HIV+prevalence+setting.&amp;publication_year=2012&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=90-97&amp;doi=10.5588%2Fijtld.11.0153&amp;pmid=22236852" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. <em>N Engl J Med</em> 2019;380:1201-1213.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1901814&amp;key=10.1056%2FNEJMoa1811867&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30865791/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000463251600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+trial+of+a+shorter+regimen+for+rifampin-resistant+tuberculosis.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=1201-1213&amp;doi=10.1056%2FNEJMoa1811867&amp;pmid=30865791" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. <em>Lancet</em> 2006;368:1575-1580.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(06)69573-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17084757/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000242180900026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Extensively+drug-resistant+tuberculosis+as+a+cause+of+death+in+patients+co-infected+with+tuberculosis+and+HIV+in+a+rural+area+of+South+Africa.&amp;publication_year=2006&amp;journal=Lancet&amp;pages=1575-1580&amp;doi=10.1016%2FS0140-6736%2806%2969573-1&amp;pmid=17084757" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">OâDonnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR Jr. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. <em>Emerg Infect Dis</em> 2013;19:416-424.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3201/eid1903.120998" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23622055/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000328173000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+outcomes+for+extensively+drug-resistant+tuberculosis+and+HIV+co-infection.&amp;publication_year=2013&amp;journal=Emerg+Infect+Dis&amp;pages=416-424&amp;doi=10.3201%2Feid1903.120998&amp;pmid=23622055" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. <em>Antimicrob Agents Chemother</em> 2009;53:1290-1292.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.01393-08" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19075053/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000263552100070" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Selectivity+of+TMC207+towards+mycobacterial+ATP+synthase+compared+with+that+towards+the+eukaryotic+homologue.&amp;publication_year=2009&amp;journal=Antimicrob+Agents+Chemother&amp;pages=1290-1292&amp;doi=10.1128%2FAAC.01393-08&amp;pmid=19075053" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. <em>Eur Respir J</em> 2016;47:564-574.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.00724-2015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26647431/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385286600027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bedaquiline+in+the+treatment+of+multidrug-+and+extensively+drug-resistant+tuberculosis.&amp;publication_year=2016&amp;journal=Eur+Respir+J&amp;pages=564-574&amp;doi=10.1183%2F13993003.00724-2015&amp;pmid=26647431" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. <em>Lancet Respir Med</em> 2018;6:699-706.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(18)30235-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30001994/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000443315800026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+bedaquiline+on+mortality+in+South+African+patients+with+drug-resistant+tuberculosis%3A+a+retrospective+cohort+study.&amp;publication_year=2018&amp;journal=Lancet+Respir+Med&amp;pages=699-706&amp;doi=10.1016%2FS2213-2600%2818%2930235-2&amp;pmid=30001994" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] confidence interval [CI], 0.18 to 0.38). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to treatment for MDR and XDR tuberculosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. <em>N Engl J Med</em> 2012;367:1508-1518.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1901814&amp;key=10.1056%2FNEJMoa1201964&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23075177/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000309904500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Linezolid+for+treatment+of+chronic+extensively+drug-resistant+tuberculosis.&amp;publication_year=2012&amp;journal=N+Engl+J+Med&amp;pages=1508-1518&amp;doi=10.1056%2FNEJMoa1201964&amp;pmid=23075177" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Yang JS, Kim KJ, Choi H, Lee SH. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. <em>Ann Lab Med</em> 2018;38:563-568.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3343/alm.2018.38.6.563" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30027700/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000442866200010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Delamanid%2C+bedaquiline%2C+and+linezolid+minimum+inhibitory+concentration+distributions+and+resistance-related+gene+mutations+in+multidrug-resistant+and+extensively+drug-resistant+tuberculosis+in+Korea.&amp;publication_year=2018&amp;journal=Ann+Lab+Med&amp;pages=563-568&amp;doi=10.3343%2Falm.2018.38.6.563&amp;pmid=30027700" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. <em>Science</em> 2008;322:1392-1395.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.1164571" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19039139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000261170600042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PA-824+kills+nonreplicating+Mycobacterium+tuberculosis+by+intracellular+NO+release.&amp;publication_year=2008&amp;journal=Science&amp;pages=1392-1395&amp;doi=10.1126%2Fscience.1164571&amp;pmid=19039139" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. <em>Commun Integr Biol</em> 2009;2:215-218.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4161/cib.2.3.7926" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19641733/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+mechanism+of+action+of+PA-824%3A+novel+insights+from+transcriptional+profiling.&amp;publication_year=2009&amp;journal=Commun+Integr+Biol&amp;pages=215-218&amp;doi=10.4161%2Fcib.2.3.7926&amp;pmid=19641733" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. <em>Antimicrob Agents Chemother</em> 2005;49:2289-2293.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.49.6.2289-2293.2005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15917523/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000229521600016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bactericidal+activity+of+the+nitroimidazopyran+PA-824+in+a+murine+model+of+tuberculosis.&amp;publication_year=2005&amp;journal=Antimicrob+Agents+Chemother&amp;pages=2289-2293&amp;doi=10.1128%2FAAC.49.6.2289-2293.2005&amp;pmid=15917523" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. <em>Nature</em> 2000;405:962-966.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/35016103" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10879539/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000087732700054" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+small-molecule+nitroimidazopyran+drug+candidate+for+the+treatment+of+tuberculosis.&amp;publication_year=2000&amp;journal=Nature&amp;pages=962-966&amp;doi=10.1038%2F35016103&amp;pmid=10879539" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. <em>Lancet</em> 2012;380:986-993.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(12)61080-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22828481/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000308746000028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=14-Day+bactericidal+activity+of+PA-824%2C+bedaquiline%2C+pyrazinamide%2C+and+moxifloxacin+combinations%3A+a+randomised+trial.&amp;publication_year=2012&amp;journal=Lancet&amp;pages=986-993&amp;doi=10.1016%2FS0140-6736%2812%2961080-0&amp;pmid=22828481" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Cherry CL, Wesselingh SL, Lal L, McArthur JC. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. <em>Neurology</em> 2005;65:1778-1781.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/01.wnl.0000187119.33075.41" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16344522/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000233898300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+a+clinical+screening+tool+for+HIV-associated+sensory+neuropathies.&amp;publication_year=2005&amp;journal=Neurology&amp;pages=1778-1781&amp;doi=10.1212%2F01.wnl.0000187119.33075.41&amp;pmid=16344522" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">National Institute of Allergy and Infectious Diseases. Division of Microbiology and Infectious Diseases (DMID) adult toxicity table November 2007 draft (<a href="https://www.niaid.nih.gov/sites/default/files/dmidadulttox.pdf">https://www.niaid.nih.gov/sites/default/files/dmidadulttox.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=National+Institute+of+Allergy+and+Infectious+Diseases.+Division+of+Microbiology+and+Infectious+Diseases+%28DMID%29+adult+toxicity+table+November+2007+draft+%28https%3A%2F%2Fwww.niaid.nih.gov%2Fsites%2Fdefault%2Ffiles%2Fdmidadulttox.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2018 (<a href="https://www.who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility/en/">https://www.who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility/en/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Technical+report+on+critical+concentrations+for+drug+susceptibility+testing+of+medicines+used+in+the+treatment+of+drug-resistant+tuberculosis.+Geneva%3A+World+Health+Organization%2C+2018+%28https%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2F2018%2FWHO_technical_report_concentrations_TB_drug_susceptibility%2Fen%2F%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Ismail NA, Omar SV, Joseph L, et al. Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study. <em>EBioMedicine</em> 2018;28:136-142.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ebiom.2018.01.005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29337135/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425875600025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+bedaquiline+susceptibility%2C+resistance%2C+cross-resistance+and+associated+genetic+determinants%3A+a+retrospective+cohort+study.&amp;publication_year=2018&amp;journal=EBioMedicine&amp;pages=136-142&amp;doi=10.1016%2Fj.ebiom.2018.01.005&amp;pmid=29337135" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019 (<a href="https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=WHO+consolidated+guidelines+on+drug-resistant+tuberculosis+treatment.+Geneva%3A+World+Health+Organization%2C+2019+%28https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F311389%2F9789241550529-eng.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatmentâ2017. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <em>Lancet</em> 2018;392:821-834.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)31644-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30215381/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000444130000028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+correlates+of+successful+outcomes+in+pulmonary+multidrug-resistant+tuberculosis%3A+an+individual+patient+data+meta-analysis.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=821-834&amp;doi=10.1016%2FS0140-6736%2818%2931644-1&amp;pmid=30215381" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. <em>Emerg Infect Dis</em> 2019;25:936-943.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3201/eid2505.181823" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31002070/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000464983500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Outcomes+of+bedaquiline+treatment+in+patients+with+multidrug-resistant+tuberculosis.&amp;publication_year=2019&amp;journal=Emerg+Infect+Dis&amp;pages=936-943&amp;doi=10.3201%2Feid2505.181823&amp;pmid=31002070" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Olayanju O, Limberis J, Esmail A, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. <em>Eur Respir J</em> 2018;51(5):1800544-1800544.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.00544-2018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29700106/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000435212900041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+bedaquiline-related+treatment+outcomes+in+patients+with+extensively+drug-resistant+tuberculosis+from+South+Africa.&amp;publication_year=2018&amp;journal=Eur+Respir+J&amp;pages=1800544-1800544&amp;doi=10.1183%2F13993003.00544-2018&amp;pmid=29700106" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. <em>Int J Tuberc Lung Dis</em> 2010;14:241-242.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20074418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000274033300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Timing+of+relapse+in+short-course+chemotherapy+trials+for+tuberculosis.&amp;publication_year=2010&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=241-242&amp;pmid=20074418" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. <em>N Engl J Med</em> 2014;371:1577-1587.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_26_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1901814&amp;key=10.1056%2FNEJMoa1407426&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25196020/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Four-month+moxifloxacin-based+regimens+for+drug-sensitive+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1577-1587&amp;doi=10.1056%2FNEJMoa1407426&amp;pmid=25196020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. <em>N Engl J Med</em> 2014;371:1599-1608.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_27_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1901814&amp;key=10.1056%2FNEJMoa1314210&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25337749/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High-dose+rifapentine+with+moxifloxacin+for+pulmonary+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1599-1608&amp;doi=10.1056%2FNEJMoa1314210&amp;pmid=25337749" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. <em>N Engl J Med</em> 2014;371:1588-1598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_28_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1901814&amp;key=10.1056%2FNEJMoa1315817&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25337748/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+four-month+gatifloxacin-containing+regimen+for+treating+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1588-1598&amp;doi=10.1056%2FNEJMoa1315817&amp;pmid=25337748" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/382/10"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">382</span></span> â¢ <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">10</span></span> â¢ <span property="datePublished">March 5, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">893</span>-<span property="pageEnd">902</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright Â© 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa1901814" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa1901814?sg=AbW1N">Chinese Translation ä¸­æç¿»è¯</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: March 4, 2020</div><div><b class="core-label">Published in issue</b>: March 5, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/global-health" alt="View article keyword Global Health" data-interactiontype="article_recirculation_click">Global Health</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/hiv-aids" alt="View article keyword HIV/AIDS" data-interactiontype="article_recirculation_click">HIV/AIDS</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/infectious-disease-general" alt="View article keyword Infectious Disease General" data-interactiontype="article_recirculation_click">Infectious Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/pulmonary-critical-care-general" alt="View article keyword Pulmonary/Critical Care General" data-interactiontype="article_recirculation_click">Pulmonary/Critical Care General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/tuberculosis" alt="View article keyword Tuberculosis" data-interactiontype="article_recirculation_click">Tuberculosis</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Francesca</span> <span property="familyName">Conradie</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andreas H.</span> <span property="familyName">Diacon</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nosipho</span> <span property="familyName">Ngubane</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pauline</span> <span property="familyName">Howell</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span>, <span property="author" typeof="Person"><span property="givenName">Daniel</span> <span property="familyName">Everitt</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Angela M.</span> <span property="familyName">Crook</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carl M.</span> <span property="familyName">Mendel</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Erica</span> <span property="familyName">Egizi</span>, <span property="honorificSuffix">M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joanna</span> <span property="familyName">Moreira</span>, <span property="honorificSuffix">B.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Juliano</span> <span property="familyName">Timm</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Timothy D.</span> <span property="familyName">McHugh</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Genevieve H.</span> <span property="familyName">Wills</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anna</span> <span property="familyName">Bateson</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert</span> <span property="familyName">Hunt</span>, <span property="honorificSuffix">B.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christo</span> <span property="familyName">Van Niekerk</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mengchun</span> <span property="familyName">Li</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Morounfolu</span> <span property="familyName">Olugbosi</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Melvin</span> <span property="familyName">Spigelman</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the Nix-TB Trial Team<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) â all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Crook at the MRC Clinical Trials Unit at UCL, 90 High Holborn, London, WC1V 6LJ, United Kingdom, or at <a href="mailto:angela.crook@ucl.ac.uk">angela.crook@ucl.ac.uk</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">Additional team members are listed in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">653</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1901814" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="9910077f-5cf9-6de8-fc26-6a55f03c638c"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366" style="display:inline-block;">
                <img alt="Article has an altmetric score of 481" src="https://badges.altmetric.com/?size=320&amp;score=481&amp;types=mabcrtfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_9910077f-5cf9-6de8-fc26-6a55f03c638c" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366&amp;tab=news">
          Picked up by <b>36</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366&amp;tab=policy-documents">
          Referenced in <b>3</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366&amp;tab=twitter">
          Posted by <b>286</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366&amp;tab=patents">
          Referenced in <b>2</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366&amp;tab=facebook">
          On <b>9</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366&amp;tab=reddit">
          Reddited by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77051366&amp;tab=guidelines">
          Referenced in <b>4</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>1030</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6199fb251622c-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1901814"> <input type="hidden" name="downloadFileName" value="csp_382_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1901814%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-10%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="653" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Pratik Mahajan, </li><li class="list-inline-item cited-by__entry__author">Hetarth R. Gor, </li><li class="list-inline-item cited-by__entry__author">Sushama Jadhav, </li><li class="list-inline-item cited-by__entry__author">Manali Joshi, </li><li class="list-inline-item cited-by__entry__author">Vijay Nema, </li></ul><span class="cited-by__entry__title">Host-Directed Therapeutic for the treatment of Mycobacterium tuberculosis, </span><span class="cited-by__entry__series-title">Microbiological Research, </span><span class="cited-by__entry__volume"><strong>299</strong>, </span><span class="cited-by__entry__page-range">(128253), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.micres.2025.128253" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.micres.2025.128253</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.micres.2025.128253" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">John W. Wilson, </li><li class="list-inline-item cited-by__entry__author">Zelalem Temesgen, </li><li class="list-inline-item cited-by__entry__author">James T. Gaensbauer, </li></ul><span class="cited-by__entry__title">Operational considerations of select new treatment recommendations for drug-susceptible and drug-resistant tuberculosis, </span><span class="cited-by__entry__series-title">Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, </span><span class="cited-by__entry__volume"><strong>40</strong>, </span><span class="cited-by__entry__page-range">(100536), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jctube.2025.100536" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jctube.2025.100536</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jctube.2025.100536" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Bella Devaleenal Daniel, </li><li class="list-inline-item cited-by__entry__author">Sivakumar Shanmugam, </li><li class="list-inline-item cited-by__entry__author">Rashi Mehta, </li><li class="list-inline-item cited-by__entry__author">Manpreet Bhalla, </li><li class="list-inline-item cited-by__entry__author">Muthuvijayalakshmi Mariappan, </li><li class="list-inline-item cited-by__entry__author">Balaji Ramraj, </li><li class="list-inline-item cited-by__entry__author">Avijit Kumar Awasthi, </li><li class="list-inline-item cited-by__entry__author">Pranav Patel, </li><li class="list-inline-item cited-by__entry__author">Amita Jain, </li><li class="list-inline-item cited-by__entry__author">Parul Jain, </li><li class="list-inline-item cited-by__entry__author">Chetan Kumar, </li><li class="list-inline-item cited-by__entry__author">Vikas Oswal, </li><li class="list-inline-item cited-by__entry__author">Neeta Singla, </li><li class="list-inline-item cited-by__entry__author">Santosh Kumar, </li><li class="list-inline-item cited-by__entry__author">Jigna Dave, </li><li class="list-inline-item cited-by__entry__author">Parul Vadgama, </li><li class="list-inline-item cited-by__entry__author">Anuj K Bhatnagar, </li><li class="list-inline-item cited-by__entry__author">Surya Kant, </li><li class="list-inline-item cited-by__entry__author">Rathinam Prabhakaran, </li><li class="list-inline-item cited-by__entry__author">Grinish Tamakuwala, </li><li class="list-inline-item cited-by__entry__author">Rishikesh Nath Mukherjee, </li><li class="list-inline-item cited-by__entry__author">Ramesh Kumar Santhanakrishnan, </li><li class="list-inline-item cited-by__entry__author">Dhandapani Ravikumar, </li><li class="list-inline-item cited-by__entry__author">Naveen kumar Nagarajan, </li><li class="list-inline-item cited-by__entry__author">Shanmugapriya Kumaravadivelu, </li><li class="list-inline-item cited-by__entry__author">Jeyadeepa Bharathi, </li><li class="list-inline-item cited-by__entry__author">Anand Sridhar, </li><li class="list-inline-item cited-by__entry__author">Ranjani Ramachandran, </li><li class="list-inline-item cited-by__entry__author">Sanjay K Matoo, </li><li class="list-inline-item cited-by__entry__author">Chinnaiyan Ponnuraja, </li><li class="list-inline-item cited-by__entry__author">Jyoti Jaju, </li><li class="list-inline-item cited-by__entry__author">Chandrasekaran Padmapriyadarsini, </li></ul><span class="cited-by__entry__title">Long&nbsp;term outcomes in drug&nbsp;resistant tuberculosis with Bedaquiline, Pretomanid and varying doses of Linezolid, </span><span class="cited-by__entry__series-title">Journal of Infection, </span><span class="cited-by__entry__volume"><strong>91</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(106509), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jinf.2025.106509" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jinf.2025.106509</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jinf.2025.106509" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Samin A. Shaikh, </li><li class="list-inline-item cited-by__entry__author">Shivaji R. Labhade, </li><li class="list-inline-item cited-by__entry__author">Santosh S. Chobe, </li><li class="list-inline-item cited-by__entry__author">Milind V. Gaikwad, </li><li class="list-inline-item cited-by__entry__author">Rahul A. More, </li><li class="list-inline-item cited-by__entry__author">Bhausaheb U. Patil, </li><li class="list-inline-item cited-by__entry__author">Deepak R. Boraste, </li></ul><span class="cited-by__entry__title">Coumarin-Triazole-Thiazole hybrids: A new avenue in Antitubercular agents, </span><span class="cited-by__entry__series-title">Bioorganic Chemistry, </span><span class="cited-by__entry__volume"><strong>161</strong>, </span><span class="cited-by__entry__page-range">(108567), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.bioorg.2025.108567" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.bioorg.2025.108567</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.bioorg.2025.108567" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">John A Buglino, </li><li class="list-inline-item cited-by__entry__author">Yaprak Ozakman, </li><li class="list-inline-item cited-by__entry__author">Chad E Hatch, </li><li class="list-inline-item cited-by__entry__author">Anna Benjamin, </li><li class="list-inline-item cited-by__entry__author">Derek S Tan, </li><li class="list-inline-item cited-by__entry__author">Michael S Glickman, </li></ul><span class="cited-by__entry__title">Chalkophore-mediated respiratory oxidase flexibility controls M. tuberculosis virulence, </span><span class="cited-by__entry__series-title">eLife, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.7554/eLife.105794.3" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.7554/eLife.105794.3</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.7554/eLife.105794.3" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">John A Buglino, </li><li class="list-inline-item cited-by__entry__author">Yaprak Ozakman, </li><li class="list-inline-item cited-by__entry__author">Chad E Hatch, </li><li class="list-inline-item cited-by__entry__author">Anna Benjamin, </li><li class="list-inline-item cited-by__entry__author">Derek S Tan, </li><li class="list-inline-item cited-by__entry__author">Michael S Glickman, </li></ul><span class="cited-by__entry__title">Chalkophore-mediated respiratory oxidase flexibility controls M. tuberculosis virulence, </span><span class="cited-by__entry__series-title">eLife, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.7554/eLife.105794" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.7554/eLife.105794</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.7554/eLife.105794" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Abdoulaye Fomba, </li><li class="list-inline-item cited-by__entry__author">Fadima C. Haidara, </li><li class="list-inline-item cited-by__entry__author">Mamoudou Kodio, </li><li class="list-inline-item cited-by__entry__author">Catherine Arama, </li><li class="list-inline-item cited-by__entry__author">Emmanuelle Cambau, </li><li class="list-inline-item cited-by__entry__author">AurÃ©lie Chauffour, </li><li class="list-inline-item cited-by__entry__author">Nicolas Veziris, </li><li class="list-inline-item cited-by__entry__author">Bettina E. Broeckling, </li><li class="list-inline-item cited-by__entry__author">Alaine K. Warren, </li><li class="list-inline-item cited-by__entry__author">Bertrand Cauchoix, </li><li class="list-inline-item cited-by__entry__author">Alexandre AlcaÃ¯s, </li><li class="list-inline-item cited-by__entry__author">Laurent Marsollier, </li><li class="list-inline-item cited-by__entry__author">Henri AssÃ©, </li><li class="list-inline-item cited-by__entry__author">Mary Jackson, </li><li class="list-inline-item cited-by__entry__author">Samba Ousmane Sow, </li><li class="list-inline-item cited-by__entry__author">Ousmane Faye, </li><li class="list-inline-item cited-by__entry__author">Vincent Jarlier, </li><li class="list-inline-item cited-by__entry__author">Stewart T. Cole, </li><li class="list-inline-item cited-by__entry__author">Charlotte Avanzi, </li><li class="list-inline-item cited-by__entry__author">Alexandra Aubry, </li><li class="list-inline-item cited-by__entry__author">Roch C. Johnson, </li></ul><span class="cited-by__entry__title">Bedaquiline Activity against Leprosy, </span><span class="cited-by__entry__series-title">New England Journal of Medicine, </span><span class="cited-by__entry__volume"><strong>392</strong>, </span><span class="cited-by__entry__issue">21, </span><span class="cited-by__entry__page-range">(2174-2176), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="/doi/full/10.1056/NEJMc2412487" title="Abstract" target="_self" class="cited-by__entry__doi">/doi/full/10.1056/NEJMc2412487</a><div class="cited-by__entry__extra-links"><a href="/doi/full/10.1056/NEJMc2412487" target="_self" class="cited-by__entry__visitable">Abstract</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Heena Soni, </li><li class="list-inline-item cited-by__entry__author">Sandeep Tyagi, </li><li class="list-inline-item cited-by__entry__author">Kishor Mane, </li><li class="list-inline-item cited-by__entry__author">Anil M. Shelke, </li><li class="list-inline-item cited-by__entry__author">Pradeep Kumar, </li><li class="list-inline-item cited-by__entry__author">Firat Kaya, </li><li class="list-inline-item cited-by__entry__author">David Alland, </li><li class="list-inline-item cited-by__entry__author">Matthew Zimmerman, </li><li class="list-inline-item cited-by__entry__author">Joel S. Freundlich, </li><li class="list-inline-item cited-by__entry__author">Eric L. Nuermberger, </li></ul><span class="cited-by__entry__title">The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis, </span><span class="cited-by__entry__series-title">Antimicrobial Agents and Chemotherapy, </span><span class="cited-by__entry__volume"><strong>69</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1128/aac.00130-25" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1128/aac.00130-25</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1128/aac.00130-25" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ying Wang, </li><li class="list-inline-item cited-by__entry__author">Daxing Cao, </li><li class="list-inline-item cited-by__entry__author">Guihua Liu, </li></ul><span class="cited-by__entry__title">Application of antimicrobial drugs in Mycobacterium tuberculosis and research progress, </span><span class="cited-by__entry__series-title">Microbial Pathogenesis, </span><span class="cited-by__entry__page-range">(107794), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.micpath.2025.107794" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.micpath.2025.107794</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.micpath.2025.107794" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Christian T. Michael, </li><li class="list-inline-item cited-by__entry__author">Maral Budak, </li><li class="list-inline-item cited-by__entry__author">Pauline Maiello, </li><li class="list-inline-item cited-by__entry__author">Kara Kracinovsky, </li><li class="list-inline-item cited-by__entry__author">Mark Rodgers, </li><li class="list-inline-item cited-by__entry__author">Jaime Tomko, </li><li class="list-inline-item cited-by__entry__author">Philana Ling Lin, </li><li class="list-inline-item cited-by__entry__author">JoAnne Flynn, </li><li class="list-inline-item cited-by__entry__author">Jennifer J. Linderman, </li><li class="list-inline-item cited-by__entry__author">Denise Kirschner, </li></ul><span class="cited-by__entry__title">Rankings of tuberculosis antibiotic treatment regimens are sensitive to spatial scale, detection limit, and initial host bacterial burden, </span><span class="cited-by__entry__series-title">Journal of Theoretical Biology, </span><span class="cited-by__entry__page-range">(112176), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jtbi.2025.112176" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jtbi.2025.112176</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jtbi.2025.112176" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1901814%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-10%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1901814" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1901814" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1901814.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1901814_f1.jpg"><img src="/cms/10.1056/NEJMoa1901814/asset/ac13821c-6eef-4f39-bb07-3558a42d705c/assets/images/large/nejmoa1901814_f1.jpg" height="3438" width="2207" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Time to an Unfavorable Outcome (Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">An unfavorable outcome was defined as treatment failure (bacteriologic or clinical) or disease relapse, with clinical treatment failure defined as a change from the protocol-specified tuberculosis treatment as a result of treatment failure, retreatment for tuberculosis, or tuberculosis-related death through follow-up until 6 months after the end of treatment. MDR denotes multidrug-resistant, and XDR extensively drug-resistant.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1901814_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1901814_f2.jpg"><img src="/cms/10.1056/NEJMoa1901814/asset/d8403b96-9bf0-4e58-9776-9c2d4b8f2986/assets/images/large/nejmoa1901814_f2.jpg" height="3438" width="2225" aria-labelledby="f2" loading="lazy"></a><figcaption>Time to Culture-Negative Status among Patients Who Were Positive at Baseline (Intention-to-Treat Population).</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1901814_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1901814/asset/260baecd-5650-4083-9b98-6010b3cedd34/assets/images/large/nejmoa1901814_t1.jpg" height="1958" width="1136" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxr-borders">Value<br>(N=109)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Median age (range) â yr</td><td class="xxxr-borders shading" data-xml-align="center">35 (17â60)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Male sex â no. (%)</td><td class="xxxr-borders" data-xml-align="center">57 (52)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race â no. (%)<a href="#core-t1fn2" role="doc-noteref">â </a></td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Black</td><td class="xxxr-borders" data-xml-align="center">83 (76)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Mixed race</td><td class="xxxr-borders shading" data-xml-align="center">25 (23)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">White</td><td class="xxxr-borders" data-xml-align="center">1 (1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Median BMI (range)<a href="#core-t1fn3" role="doc-noteref">â¡</a></td><td class="xxxr-borders shading" data-xml-align="center">19.7 (12.4â41.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">HIV-positive â no. (%)</td><td class="xxxr-borders" data-xml-align="center">56 (51)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Median time since HIV diagnosis (range) â yr</td><td class="xxxr-borders shading" data-xml-align="center">4.0 (0.2â14.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Median CD4 cell count (range) â cells/mm<sup>3</sup><a href="#core-t1fn4" role="doc-noteref">Â§</a></td><td class="xxxr-borders" data-xml-align="center">343 (55â1023)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Cavities present on chest radiograph â no. (%)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">No</td><td class="xxxr-borders" data-xml-align="center">17 (16)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Unilateral</td><td class="xxxr-borders shading" data-xml-align="center">51 (47)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Bilateral</td><td class="xxxr-borders" data-xml-align="center">41 (38)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Karnofsky score â no. (%)<a href="#core-t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">100</td><td class="xxxr-borders" data-xml-align="center">9 (8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">90</td><td class="xxxr-borders shading" data-xml-align="center">50 (46)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">80</td><td class="xxxr-borders" data-xml-align="center">29 (27)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">70</td><td class="xxxr-borders shading" data-xml-align="center">19 (17)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">60</td><td class="xxxr-borders" data-xml-align="center">2 (2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">&lt;60</td><td class="xxxr-borders shading" data-xml-align="center">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Median no. of tuberculosis drugs taken in month before enrollment (range)</td><td class="xxxr-borders" data-xml-align="center">7 (3â13)</td></tr><tr data-type="row"><td class="xblx-borders hanging02 shading">Median time since original tuberculosis diagnosis (range) â mo</td><td class="xbxr-borders shading" data-xml-align="center">12 (&lt;1â141)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Percentages may not total 100 because of rounding. HIV denotes human immunodeficiency virus.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Data on CD4 cell count were missing for 5 patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">The Karnofsky score ranges from 0 to 100, with lower scores indicating greater disability.</div></div></div></figcaption></a><figcaption><div class="caption">Baseline Characteristics of the Patients.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1901814/asset/38a2bee1-1a84-41a0-8d74-531bd27bc18b/assets/images/large/nejmoa1901814_t2.jpg" height="2263" width="1712" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">XDR</th><th class="txxx-borders">MDR</th><th class="txxr-borders">Overall</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Intention-to-treat population</b><a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">71</td><td class="xxxx-borders">38</td><td class="xxxr-borders">109</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Favorable outcome</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients</td><td class="xxxx-borders">63</td><td class="xxxx-borders">35</td><td class="xxxr-borders">98</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders shading">89 (79â95)</td><td class="xxxx-borders shading">92 (79â98)</td><td class="xxxr-borders shading">90 (83â95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Unfavorable outcome â no. (%)</td><td class="xxxx-borders">8 (11)</td><td class="xxxx-borders">3 (8)</td><td class="xxxr-borders">11 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Deaths â no.</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Withdrawal during treatment â no.</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Lost to follow-up after end of treatment â no.</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Relapse â no.</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1</td><td class="xxxr-borders">2<a href="#core-t2fn3" role="doc-noteref">â¡</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Modified intention-to-treat population</b><a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">70</td><td class="xxxx-borders">37</td><td class="xxxr-borders">107</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Favorable outcome</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients</td><td class="xxxx-borders">63</td><td class="xxxx-borders">35</td><td class="xxxr-borders">98</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders shading">90 (80â96)</td><td class="xxxx-borders shading">95 (82â99)</td><td class="xxxr-borders shading">92 (85â96)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Unfavorable outcome â no. (%)</td><td class="xxxx-borders">7 (10)</td><td class="xxxx-borders">2 (5)</td><td class="xxxr-borders">9 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Deaths â no.</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Withdrawal during treatment â no.</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Relapse â no.</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">2<a href="#core-t2fn3" role="doc-noteref">â¡</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Per-protocol population</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">68</td><td class="xxxx-borders shading">37</td><td class="xxxr-borders shading">105</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Favorable outcome</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">62</td><td class="xxxx-borders shading">35</td><td class="xxxr-borders shading">97</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders">91 (82â97)</td><td class="xxxx-borders">95 (82â99)</td><td class="xxxr-borders">92 (86â97)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Unfavorable outcome â no. (%)</td><td class="xxxx-borders shading">6 (9)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxr-borders shading">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Deaths â no.</td><td class="xxxx-borders">5</td><td class="xxxx-borders">1</td><td class="xxxr-borders">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Relapse â no.</td><td class="xbxx-borders shading">1</td><td class="xbxx-borders shading">1</td><td class="xbxr-borders shading">2<a href="#core-t2fn3" role="doc-noteref">â¡</a></td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">An unfavorable outcome was defined as treatment failure (bacteriologic or clinical) or disease relapse, with clinical treatment failure defined as a change from the protocol-specified tuberculosis treatment as a result of treatment failure, retreatment for tuberculosis, or tuberculosis-related death through follow-up until 6 months after the end of treatment. Patients were considered to have had a favorable outcome if their clinical tuberculosis disease had resolved, they had a negative culture status at 6 months after the end of therapy, and they had not already been classified as having had an unfavorable outcome. All patients in this study had either a favorable or an unfavorable outcome at 6 months after the end of treatment.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The intention-to-treat and modified intention-to-treat analyses were prespecified in the protocol. Two patients were excluded from the modified intention-to-treat population: one who died from nonâtuberculosis-related causes during follow-up, and one who was lost to follow-up after the end of treatment. Two additional patients were excluded from the per-protocol population: one who received an inadequate amount of drug, and one who was withdrawn (not for treatment failure) during treatment.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">A baseline isolate was not available for one patient who had a relapse.</div></div></div></figcaption></a><figcaption><div class="caption">Primary Efficacy Analysis.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1901814/asset/96a0a1ed-9765-46b1-a3bf-f349d1fb9951/assets/images/large/nejmoa1901814_t3.jpg" height="714" width="1712" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event<a href="#core-t3fn1" role="doc-noteref">*</a></th><th class="txxx-borders" colspan="2"><span>HIV Status</span></th><th class="txxx-borders" colspan="2"><span>Linezolid Regimen</span></th><th class="txxr-borders">Overall<br>(N=109)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Negative<br>(N=53)</th><th class="xxxx-borders">Positive<br>(N=56)</th><th class="xxxx-borders">600 mg Twice Daily<br>(N=44)</th><th class="xxxx-borders">1200 mg Daily<br>(N=65)</th><th class="xxxr-borders">&nbsp;</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="5"><span>number (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Adverse event</td><td class="xxxx-borders shading">53 (100)</td><td class="xxxx-borders shading">56 (100)</td><td class="xxxx-borders shading">44 (100)</td><td class="xxxx-borders shading">65 (100)</td><td class="xxxr-borders shading">109 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Adverse event leading to death</td><td class="xxxx-borders">3 (6)</td><td class="xxxx-borders">3 (5)</td><td class="xxxx-borders">4 (9)</td><td class="xxxx-borders">2 (3)</td><td class="xxxr-borders">6 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">10 (19)</td><td class="xxxx-borders shading">9 (16)</td><td class="xxxx-borders shading">13 (30)</td><td class="xxxx-borders shading">6 (9)</td><td class="xxxr-borders shading">19 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Grade 3 or 4 adverse event</td><td class="xbxx-borders">27 (51)</td><td class="xbxx-borders">35 (62)</td><td class="xbxx-borders">27 (61)</td><td class="xbxx-borders">35 (54)</td><td class="xbxr-borders">62 (57)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">A patient could have had more than one type of event.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events That Occurred or Worsened during Treatment.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1901814_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1901814</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">The end TB strategy. Geneva: World Health Organization, 2014 (<a href="http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1">http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=The+end+TB+strategy.+Geneva%3A+World+Health+Organization%2C+2014+%28http%3A%2F%2Fwww.who.int%2Ftb%2Fstrategy%2FEnd_TB_Strategy.pdf%3Fua%3D1%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Gandhi NR, Andrews JR, Brust JC, et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. <em>Int J Tuberc Lung Dis</em> 2012;16:90-97.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5588/ijtld.11.0153" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22236852/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000298726700017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+factors+for+mortality+among+MDR-+and+XDR-TB+patients+in+a+high+HIV+prevalence+setting.&amp;publication_year=2012&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=90-97&amp;doi=10.5588%2Fijtld.11.0153&amp;pmid=22236852" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. <em>N Engl J Med</em> 2019;380:1201-1213.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1901814&amp;key=10.1056%2FNEJMoa1811867&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30865791/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000463251600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+trial+of+a+shorter+regimen+for+rifampin-resistant+tuberculosis.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=1201-1213&amp;doi=10.1056%2FNEJMoa1811867&amp;pmid=30865791" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. <em>Lancet</em> 2006;368:1575-1580.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(06)69573-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17084757/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000242180900026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Extensively+drug-resistant+tuberculosis+as+a+cause+of+death+in+patients+co-infected+with+tuberculosis+and+HIV+in+a+rural+area+of+South+Africa.&amp;publication_year=2006&amp;journal=Lancet&amp;pages=1575-1580&amp;doi=10.1016%2FS0140-6736%2806%2969573-1&amp;pmid=17084757" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">OâDonnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR Jr. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. <em>Emerg Infect Dis</em> 2013;19:416-424.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3201/eid1903.120998" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23622055/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000328173000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+outcomes+for+extensively+drug-resistant+tuberculosis+and+HIV+co-infection.&amp;publication_year=2013&amp;journal=Emerg+Infect+Dis&amp;pages=416-424&amp;doi=10.3201%2Feid1903.120998&amp;pmid=23622055" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. <em>Antimicrob Agents Chemother</em> 2009;53:1290-1292.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.01393-08" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19075053/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000263552100070" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Selectivity+of+TMC207+towards+mycobacterial+ATP+synthase+compared+with+that+towards+the+eukaryotic+homologue.&amp;publication_year=2009&amp;journal=Antimicrob+Agents+Chemother&amp;pages=1290-1292&amp;doi=10.1128%2FAAC.01393-08&amp;pmid=19075053" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. <em>Eur Respir J</em> 2016;47:564-574.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.00724-2015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26647431/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385286600027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bedaquiline+in+the+treatment+of+multidrug-+and+extensively+drug-resistant+tuberculosis.&amp;publication_year=2016&amp;journal=Eur+Respir+J&amp;pages=564-574&amp;doi=10.1183%2F13993003.00724-2015&amp;pmid=26647431" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. <em>Lancet Respir Med</em> 2018;6:699-706.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(18)30235-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30001994/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000443315800026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+bedaquiline+on+mortality+in+South+African+patients+with+drug-resistant+tuberculosis%3A+a+retrospective+cohort+study.&amp;publication_year=2018&amp;journal=Lancet+Respir+Med&amp;pages=699-706&amp;doi=10.1016%2FS2213-2600%2818%2930235-2&amp;pmid=30001994" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] confidence interval [CI], 0.18 to 0.38). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to treatment for MDR and XDR tuberculosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. <em>N Engl J Med</em> 2012;367:1508-1518.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1901814&amp;key=10.1056%2FNEJMoa1201964&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23075177/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000309904500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Linezolid+for+treatment+of+chronic+extensively+drug-resistant+tuberculosis.&amp;publication_year=2012&amp;journal=N+Engl+J+Med&amp;pages=1508-1518&amp;doi=10.1056%2FNEJMoa1201964&amp;pmid=23075177" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Yang JS, Kim KJ, Choi H, Lee SH. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. <em>Ann Lab Med</em> 2018;38:563-568.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3343/alm.2018.38.6.563" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30027700/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000442866200010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Delamanid%2C+bedaquiline%2C+and+linezolid+minimum+inhibitory+concentration+distributions+and+resistance-related+gene+mutations+in+multidrug-resistant+and+extensively+drug-resistant+tuberculosis+in+Korea.&amp;publication_year=2018&amp;journal=Ann+Lab+Med&amp;pages=563-568&amp;doi=10.3343%2Falm.2018.38.6.563&amp;pmid=30027700" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. <em>Science</em> 2008;322:1392-1395.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.1164571" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19039139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000261170600042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PA-824+kills+nonreplicating+Mycobacterium+tuberculosis+by+intracellular+NO+release.&amp;publication_year=2008&amp;journal=Science&amp;pages=1392-1395&amp;doi=10.1126%2Fscience.1164571&amp;pmid=19039139" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. <em>Commun Integr Biol</em> 2009;2:215-218.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4161/cib.2.3.7926" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19641733/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+mechanism+of+action+of+PA-824%3A+novel+insights+from+transcriptional+profiling.&amp;publication_year=2009&amp;journal=Commun+Integr+Biol&amp;pages=215-218&amp;doi=10.4161%2Fcib.2.3.7926&amp;pmid=19641733" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. <em>Antimicrob Agents Chemother</em> 2005;49:2289-2293.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.49.6.2289-2293.2005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15917523/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000229521600016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bactericidal+activity+of+the+nitroimidazopyran+PA-824+in+a+murine+model+of+tuberculosis.&amp;publication_year=2005&amp;journal=Antimicrob+Agents+Chemother&amp;pages=2289-2293&amp;doi=10.1128%2FAAC.49.6.2289-2293.2005&amp;pmid=15917523" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. <em>Nature</em> 2000;405:962-966.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/35016103" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10879539/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000087732700054" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+small-molecule+nitroimidazopyran+drug+candidate+for+the+treatment+of+tuberculosis.&amp;publication_year=2000&amp;journal=Nature&amp;pages=962-966&amp;doi=10.1038%2F35016103&amp;pmid=10879539" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. <em>Lancet</em> 2012;380:986-993.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(12)61080-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22828481/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000308746000028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=14-Day+bactericidal+activity+of+PA-824%2C+bedaquiline%2C+pyrazinamide%2C+and+moxifloxacin+combinations%3A+a+randomised+trial.&amp;publication_year=2012&amp;journal=Lancet&amp;pages=986-993&amp;doi=10.1016%2FS0140-6736%2812%2961080-0&amp;pmid=22828481" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Cherry CL, Wesselingh SL, Lal L, McArthur JC. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. <em>Neurology</em> 2005;65:1778-1781.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/01.wnl.0000187119.33075.41" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16344522/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000233898300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+a+clinical+screening+tool+for+HIV-associated+sensory+neuropathies.&amp;publication_year=2005&amp;journal=Neurology&amp;pages=1778-1781&amp;doi=10.1212%2F01.wnl.0000187119.33075.41&amp;pmid=16344522" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">National Institute of Allergy and Infectious Diseases. Division of Microbiology and Infectious Diseases (DMID) adult toxicity table November 2007 draft (<a href="https://www.niaid.nih.gov/sites/default/files/dmidadulttox.pdf">https://www.niaid.nih.gov/sites/default/files/dmidadulttox.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=National+Institute+of+Allergy+and+Infectious+Diseases.+Division+of+Microbiology+and+Infectious+Diseases+%28DMID%29+adult+toxicity+table+November+2007+draft+%28https%3A%2F%2Fwww.niaid.nih.gov%2Fsites%2Fdefault%2Ffiles%2Fdmidadulttox.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2018 (<a href="https://www.who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility/en/">https://www.who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility/en/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Technical+report+on+critical+concentrations+for+drug+susceptibility+testing+of+medicines+used+in+the+treatment+of+drug-resistant+tuberculosis.+Geneva%3A+World+Health+Organization%2C+2018+%28https%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2F2018%2FWHO_technical_report_concentrations_TB_drug_susceptibility%2Fen%2F%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Ismail NA, Omar SV, Joseph L, et al. Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study. <em>EBioMedicine</em> 2018;28:136-142.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ebiom.2018.01.005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29337135/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425875600025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+bedaquiline+susceptibility%2C+resistance%2C+cross-resistance+and+associated+genetic+determinants%3A+a+retrospective+cohort+study.&amp;publication_year=2018&amp;journal=EBioMedicine&amp;pages=136-142&amp;doi=10.1016%2Fj.ebiom.2018.01.005&amp;pmid=29337135" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019 (<a href="https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=WHO+consolidated+guidelines+on+drug-resistant+tuberculosis+treatment.+Geneva%3A+World+Health+Organization%2C+2019+%28https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F311389%2F9789241550529-eng.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatmentâ2017. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <em>Lancet</em> 2018;392:821-834.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)31644-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30215381/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000444130000028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+correlates+of+successful+outcomes+in+pulmonary+multidrug-resistant+tuberculosis%3A+an+individual+patient+data+meta-analysis.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=821-834&amp;doi=10.1016%2FS0140-6736%2818%2931644-1&amp;pmid=30215381" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. <em>Emerg Infect Dis</em> 2019;25:936-943.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3201/eid2505.181823" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31002070/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000464983500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Outcomes+of+bedaquiline+treatment+in+patients+with+multidrug-resistant+tuberculosis.&amp;publication_year=2019&amp;journal=Emerg+Infect+Dis&amp;pages=936-943&amp;doi=10.3201%2Feid2505.181823&amp;pmid=31002070" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Olayanju O, Limberis J, Esmail A, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. <em>Eur Respir J</em> 2018;51(5):1800544-1800544.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.00544-2018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29700106/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000435212900041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+bedaquiline-related+treatment+outcomes+in+patients+with+extensively+drug-resistant+tuberculosis+from+South+Africa.&amp;publication_year=2018&amp;journal=Eur+Respir+J&amp;pages=1800544-1800544&amp;doi=10.1183%2F13993003.00544-2018&amp;pmid=29700106" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. <em>Int J Tuberc Lung Dis</em> 2010;14:241-242.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20074418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000274033300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Timing+of+relapse+in+short-course+chemotherapy+trials+for+tuberculosis.&amp;publication_year=2010&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=241-242&amp;pmid=20074418" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. <em>N Engl J Med</em> 2014;371:1577-1587.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_26_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1901814&amp;key=10.1056%2FNEJMoa1407426&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25196020/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Four-month+moxifloxacin-based+regimens+for+drug-sensitive+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1577-1587&amp;doi=10.1056%2FNEJMoa1407426&amp;pmid=25196020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. <em>N Engl J Med</em> 2014;371:1599-1608.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_27_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1901814&amp;key=10.1056%2FNEJMoa1314210&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25337749/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High-dose+rifapentine+with+moxifloxacin+for+pulmonary+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1599-1608&amp;doi=10.1056%2FNEJMoa1314210&amp;pmid=25337749" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. <em>N Engl J Med</em> 2014;371:1588-1598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_28_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1901814&amp;key=10.1056%2FNEJMoa1315817&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25337748/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+four-month+gatifloxacin-containing+regimen+for+treating+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1588-1598&amp;doi=10.1056%2FNEJMoa1315817&amp;pmid=25337748" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 10, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2009939" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Treatment of Highly Drug-Resistant Pulmonary Tuberculosis</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 04, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2000860" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Triumph and Tragedy of 21st Century Tuberculosis Drug Development</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">G. Thwaites and P. Nahid</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/865656/division-chief-practice-lead-neurology-opportunity-in-the-beautiful-berkshires-of-western-ma-/?query=fjwp&amp;rid=886">Division Chief/ Practice Lead Neurology Opportunity in the Beautiful Berkshires of Western MA!</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/875196/breast-surgeon-texas-oncology-austin/?query=fjwp&amp;rid=5696">Breast Surgeon - Texas Oncology Austin</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/878594/hematology-opening-30-minutes-from-boston-ma-ip-op-split/?query=fjwf&amp;rid=475926">Hematology Opening 30 Minutes from Boston, MA | IP/OP Split</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/674710/vice-chair-brachytherapy-nassau-county-long-island-northwell-health/?query=fjwp&amp;rid=3059">Vice Chair, Brachytherapy - Nassau County, Long Island, Northwell Health</a></div></div><div class="nejm-widget_item"><div><span> Detroit, Michigan</span></div><div><span>Infectious Disease</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886133/system-associate-med-director-of-epidemiology-and-infection-prevention-and-antimicrobial-stewardship/?query=fjwp&amp;rid=4557">System Associate Med Director of Epidemiology and Infection Prevention and Antimicrobial Stewardship</a></div></div><div class="nejm-widget_item"><div><span> Portland, Oregon</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879700/child-and-adolescent-psychiatry-physician/?query=fjwf&amp;rid=329661">Child and Adolescent Psychiatry Physician</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1901814&amp;pubId=41288134&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6199fb251622c-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6199fb251622c-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6199fb251622c-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$416216633$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$416216633$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$416216633$--></div></div><div class="mlt-body"><!--?lit$416216633$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$416216633$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$416216633$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$416216633$-->Sep 01, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2119430?query=recirc_Semantic" target="_self">BedaquilineâPretomanidâLinezolid Regimens for Drug-Resistant Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$416216633$-->F. Conradie and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$416216633$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$416216633$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$416216633$-->Jan 30, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2400327?query=recirc_Semantic" target="_self">Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$416216633$-->L. Guglielmetti and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$416216633$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$416216633$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$416216633$-->Dec 22, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2117166?query=recirc_Semantic" target="_self">A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$416216633$-->B.-T. Nyangâwa and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$416216633$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$416216633$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$416216633$-->Sep 01, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2119461?query=recirc_Semantic" target="_self">Pretomanid in the Treatment of Patients with Tuberculosis in the United States</a></div><div class="mlt-article-authors"><!--?lit$416216633$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$416216633$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$416216633$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$416216633$-->Mar 09, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2212537?query=recirc_Semantic" target="_self">Treatment Strategy for Rifampin-Susceptible Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$416216633$-->N.I. Paton and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1901814?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1901814" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1901814.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1901814"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Treatment of Highly Drug-Resistant Pulmonary Tuberculosis</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp1913106" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>What Are Two Days Worth? Facing Dilemmas Together at the End of Life</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa1911614" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin â Final Report</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1901814_f1.jpg"><img src="/cms/10.1056/NEJMoa1901814/asset/ac13821c-6eef-4f39-bb07-3558a42d705c/assets/images/large/nejmoa1901814_f1.jpg" height="3438" width="2207" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Time to an Unfavorable Outcome (Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">An unfavorable outcome was defined as treatment failure (bacteriologic or clinical) or disease relapse, with clinical treatment failure defined as a change from the protocol-specified tuberculosis treatment as a result of treatment failure, retreatment for tuberculosis, or tuberculosis-related death through follow-up until 6 months after the end of treatment. MDR denotes multidrug-resistant, and XDR extensively drug-resistant.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1901814_f2.jpg"><img src="/cms/10.1056/NEJMoa1901814/asset/d8403b96-9bf0-4e58-9776-9c2d4b8f2986/assets/images/large/nejmoa1901814_f2.jpg" height="3438" width="2225" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption>Time to Culture-Negative Status among Patients Who Were Positive at Baseline (Intention-to-Treat Population).</figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Baseline Characteristics of the Patients.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary Efficacy Analysis.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events That Occurred or Worsened during Treatment.</div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/382/10" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 382 No. 10</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 05, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2001191" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: First Case of 2019 Novel Coronavirus in the United States</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.L. Holshue and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 05, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1910038" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M. Ahdoot and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 05, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1911614" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin â Final Report</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.E. Layden and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1901814%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1901814&amp;pubId=41288134&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1901814%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1901814&amp;pubId=41288134&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright Â© 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id06079343259749302" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6199fb251622c-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6199fb251622c-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6199fb251622c-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6199fb251622c-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6199fb251622c-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6199fb251622c-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6199fb251622c-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6199fb251622c-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6199fb251622c-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6199fb251622c-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6199f988a622c',t:'MTc0OTUyOTQ3Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6199f988a622c&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">â</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">Moreâ¦</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><fxb-ngnpxofvugoo></fxb-ngnpxofvugoo><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1901814?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-transactionid="bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" id="captureIFrame_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" target="captureIFrame_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="â" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="capture_screen"><input id="capture_signIn_js_version_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="js_version"><input id="capture_signIn_transactionId_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" type="hidden" class="capture_transactionId_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="capture_transactionId"><input id="capture_signIn_form_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="form"><input id="capture_signIn_flow_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="flow"><input id="capture_signIn_client_id_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="client_id"><input id="capture_signIn_redirect_uri_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="redirect_uri"><input id="capture_signIn_response_type_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="response_type"><input id="capture_signIn_flow_version_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="flow_version"><input id="capture_signIn_settings_version_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="settings_version"><input id="capture_signIn_locale_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="locale"><input id="capture_signIn_recaptcha_version_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_bq1w4pi4vl40tqw5orq52l8umkponle0n9hg947u" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>